Free Trial
Paul Jeng

Paul Jeng Analyst Performance

Vice President at Guggenheim

Paul Jeng is a stock analyst at Guggenheim in the medical sector, covering 6 publicly traded companies. Over the past year, Paul Jeng has issued 13 stock ratings, including buy and hold recommendations. While full access to Paul Jeng's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Paul Jeng's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 0 Years
Buy Recommendations
92.31% 12 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy92.3%12 ratings
Hold7.7%1 ratings
Sell0.0%0 ratings

Out of 13 total stock ratings issued by Paul Jeng at Guggenheim, the majority (92.3%) have been Buy recommendations, followed by 7.7% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
6 companies

Paul Jeng, an analyst at Guggenheim, currently covers 6 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
100.0%

Paul Jeng of Guggenheim specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
4 companies
66.7%
MED - DRUGS
2 companies
33.3%

Paul Jeng's Ratings History at Guggenheim

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
4/29/2026Initiated Coverage$9.82$45.00Buy
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
4/29/2026Initiated Coverage$9.88$45.00Buy
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
4/14/2026Boost Price Target$32.82$54.00Buy
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
4/6/2026Boost Price Target$3.99$10.00Buy
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
3/24/2026Reiterated Rating$3.20$5.00Buy
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2/18/2026Reiterated Rating$31.03$50.00Buy
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
11/24/2025Initiated Coverage$1.80$9.00Buy
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
11/24/2025Initiated Coverage$1.99$9.00Buy
Immatics N.V. stock logo
IMTX
Immatics
11/18/2025Boost Price Target$9.32$19.00Buy
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
9/18/2025Initiated Coverage$0.88$5.00Buy
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
9/18/2025Initiated Coverage$24.44$50.00Buy
Immatics N.V. stock logo
IMTX
Immatics
9/18/2025Initiated Coverage$6.03$16.00Buy
Immunocore Holdings PLC Sponsored ADR stock logo
IMCR
Immunocore
9/18/2025Initiated Coverage$33.95Neutral